Holen Sie sich die Stockscreener-App
6.36
18.30%
-1.48
Cns Pharmaceuticals Inc Aktie (CNSP) Neueste Nachrichten
CNS Pharma sees 250% spike from oversubscribed private placement - Mugglehead Investment Magazine
CNS Pharmaceuticals (CNSP) Stock Skyrockets 215% on $22.5M Funding Round - MEXC
CNSP Secures $22.5 Million in Private Placement Financing - GuruFocus
CNS Pharmaceuticals (CNSP) Stock Skyrockets 215% on $22.5M Fundraise - MEXC
CNS Pharmaceuticals Raises $22.5 Million in Private Placement to Fuel Asset Acquisition - MEXC
CNS Pharmaceuticals (NASDAQ: CNSP) Secures $22.5M Private Placement Financing - The Globe and Mail
Gold Falls Over 2%; US Factory Orders Rise In March - Benzinga
CNS Pharmaceuticals Announces Private Placement Agreement and Pre-Funded Warrants Offering – Details and Legal Terms - Minichart
Why is CNS Pharmaceuticals stock up 250% today? By Investing.com - Investing.com Nigeria
Nano-cap CNS Pharmaceuticals stock explodes as capital raise fuels pivot - MSN
Why is CNS Pharmaceuticals stock up 250% today? - Investing.com
CNS Pharmaceuticals raises $22.5 million in private placement By Investing.com - Investing.com South Africa
Trending Stocks Today | CNS Pharmaceuticals Soars 280.77% - Moomoo
Why CNS Pharmaceuticals (CNSP) Stock Is Up 215% Today - CoinCentral
CNSP Stock Explodes Higher As Traders Hunt Volatility - StocksToTrade
Why Is CNS Pharmaceuticals Stock (CNSP) Up Today? - TipRanks
Why Did CNSP Stock Surge 330% Today? - Stocktwits
Dow Falls Over 150 Points; Tyson Foods Posts Upbeat Earnings - Benzinga
Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot - Benzinga
CNSP Stock Volatility Spikes As Traders Watch Key Levels - timothysykes.com
CNS Pharmaceuticals prices 650,000 shares at $2.30 in private placement - TipRanks
CNS Pharmaceuticals raises $22.5 million in private placement - Investing.com
CNS Pharmaceuticals Announces Private Placement and Board Changes - TipRanks
CNS Pharmaceuticals Raises $22.5 Million in Private Placement; Signs Registration and Placement Deals - TradingView
CNS Pharmaceuticals (NASDAQ: CNSP) completes $22.5M private placement and board change - Stock Titan
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing - ACCESS Newswire
Biotech CNS raises $22.5M to buy clinical-stage drug assets - Stock Titan
CNS Pharmaceuticals, Inc. 2025 Annual Report: Executive Compensation, Governance, and Audit Details - Minichart
CNS Pharmaceuticals (NASDAQ: CNSP) details CEO transition, pay and ownership in 10-K/A - Stock Titan
CNS Pharmaceuticals Inc. (CNSP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CNS Pharmaceuticals Inc. (CNSP) shares fall 3.27% after posting a far wider than expected Q4 2025 per-share loss. - Cổng thông tin điện tử Tỉnh Sơn La
CNS Pharma (CNSP) Stock: Is It Showing Downtrend Signals | Q4 2025: Profit Disappoints - Cổng thông tin điện tử Tỉnh Sơn La
Is CNS Pharma (CNSP) stock showing technical strength (Smart Money Outflows) 2026-04-18Trader Community Insights - Xã Vĩnh Công
Ikarian group holds 5.7% of CNS Pharmaceuticals (NASDAQ: CNSP) - Stock Titan
AtaiBeckley (ATAI) Reports Phase 2a Data in CNS Drugs - Yahoo Finance
Gains Report: Is CNS Pharmaceuticals Inc being accumulated by smart money2026 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
Is CNS Pharma (CNSP) Stock Underperforming | CNSP Q4 Earnings: Misses Estimates by $4.96Market Hype Signals - Cổng thông tin điện tử tỉnh Lào Cai
Profit Recap: Why is CNS Pharmaceuticals Inc stock going down2026 Macro Impact & Smart Swing Trading Alerts - baoquankhu1.vn
Exit Recap: Is CNS Pharmaceuticals Inc in a long term uptrend2026 Valuation Update & Daily Stock Momentum Reports - baoquankhu1.vn
CNS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
CNSP PE Ratio & Valuation, Is CNSP Overvalued - Intellectia AI
CNS Pharmaceuticals | 10-K: Annual report - Moomoo
CNS Pharmaceuticals 10-K: Net loss $15.85M, Loss per share $35.75 - TradingView — Track All Markets
CNS Pharmaceuticals (NASDAQ: CNSP) pivots to neurology and oncology amid going concern risk - Stock Titan
Pharma News: Will CNS Pharmaceuticals Inc outperform small cap indexesDip Buying & Verified Short-Term Trading Plans - baoquankhu1.vn
CNS Pharmaceuticals Inc expected to post a loss of $5.09 a shareEarnings Preview - TradingView
Lunai Bioworks, Inc. (LNAI) Stock: No-Reset Convertible Deal Boosts CNS Drug Development Edge - parameter.io
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications - PR Newswire
Is CNS Pharmaceuticals Inc in a long term uptrend2026 Earnings & Real-Time Market Sentiment Reports - baoquankhu1.vn
Stop Loss: Will CNS Pharmaceuticals Inc outperform small cap indexesPortfolio Performance Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Aug Decliners: Is CNS Pharmaceuticals Inc forming a bullish divergence2026 Biggest Moves & Weekly Return Optimization Plans - baoquankhu1.vn
Movement Recap: Is CNS Pharmaceuticals Inc stock good for income investors2026 Movers & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Death Cross: Is CNS Pharmaceuticals Inc forming a bullish divergence2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Will CNS Pharmaceuticals Inc stock go up in YEARWeekly Earnings Recap & Verified Swing Trading Watchlists - baoquankhu1.vn
CNS Pharmaceuticals shifts focus to neurology, oncology assets By Investing.com - Investing.com Nigeria
Quarterly Trades: Is CNS Pharmaceuticals Inc currently under institutional pressure2026 Trading Recap & Long-Term Capital Growth Strategies - baoquankhu1.vn
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Business Wire
CNS Pharmaceuticals Unveils Strategic Pivot to Broader Oncology - The Globe and Mail
1.94%
1.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):